{"title":"综合研究表明GLP-1对神经精神有益处","authors":"","doi":"10.1002/pu.31301","DOIUrl":null,"url":null,"abstract":"<p>A study evaluating the effects of glucagon-like peptide-1 (GLP-1) receptor agonists on 175 health outcomes found an association with lower risk of substance use, psychotic, and neurocognitive disorders in patients diagnosed with diabetes. Conversely, use of GLP-1 drugs was associated with higher risk of gastrointestinal disorders.</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 5","pages":"4-5"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Comprehensive study of GLP-1 effects suggests neuropsychiatric benefits\",\"authors\":\"\",\"doi\":\"10.1002/pu.31301\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>A study evaluating the effects of glucagon-like peptide-1 (GLP-1) receptor agonists on 175 health outcomes found an association with lower risk of substance use, psychotic, and neurocognitive disorders in patients diagnosed with diabetes. Conversely, use of GLP-1 drugs was associated with higher risk of gastrointestinal disorders.</p>\",\"PeriodicalId\":22275,\"journal\":{\"name\":\"The Brown University Psychopharmacology Update\",\"volume\":\"36 5\",\"pages\":\"4-5\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-03-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Brown University Psychopharmacology Update\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/pu.31301\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Brown University Psychopharmacology Update","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/pu.31301","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Comprehensive study of GLP-1 effects suggests neuropsychiatric benefits
A study evaluating the effects of glucagon-like peptide-1 (GLP-1) receptor agonists on 175 health outcomes found an association with lower risk of substance use, psychotic, and neurocognitive disorders in patients diagnosed with diabetes. Conversely, use of GLP-1 drugs was associated with higher risk of gastrointestinal disorders.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
